With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23687-25-4,Isoquinolin-4-amine,as a common compound, the synthetic route is as follows.
23687-25-4, Example 2282-(cyclopentanecarboxamido)-N-(isoquinolin-4-yl)isonicotinamideIn a 5 mL round-bottom flask was dissolved 2-(cyclopentanecarboxamido)isonicotinic acid (36 mg, 0.154 mmol) and isoquinolin-4-amine (26.6 mg, 0.184 mmol) in dimethylformamide (0.8 mL) to give a tan solution. HATU (117 mg, 0.307 mmol) and Hunig’sBase (0.054 mL, 0.307 mmol) were added, and the mixture was stirred at rt overnight for 19 h. The desired product was obtained by prep-HPLC (5.9 mg, 10%): MS (ESI) (m/z): 361 (M+H)+; 1H NMR (400 MHz, DMSO) delta 10.81 (s, IH), 10.67 (s, IH), 9.32 (s, IH), 8.69 (s, IH), 8.65 (s, IH), 8.59 – 8.51 (m, IH), 8.30 – 8.20 (m, IH), 8.07 – 7.99 (m, IH), 7.91 – 7.84 (m, IH), 7.82 – 7.74 (m, IH), 7.73 – 7.66 (m, IH), 3.05 – 2.98 (m, IH), 1.95 – 1.85 (m, 2H), 1.83 – 1.66 (m, 4H), 1.64 – 1.54 (m, 2H).
As the paragraph descriping shows that 23687-25-4 is playing an increasingly important role.
Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; LUO, Guanglin; CHEN, Ling; DUBOWCHIK, Gene M.; JACUTIN-PORTE, Swanee E.; SIVAPRAKASAM, Prasanna; MACOR, John E.; WO2015/69593; (2015); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem